BRANCHBURG, N.J., July 21 /PRNewswire/ -- LifeCell Corporation announces the following Webcast:
What: LifeCell Corporation Second Quarter 2004 Financial Results Conference Call Webcast When: July 22, 2004 @ 11:00 AM Eastern Where: http://www.vcall.com/EventPage.asp?ID=88641 How: Live over the Internet -- Simply log on to the web at the address above. Contact: Marian Smith, (908) 947-1100 or msmith@lifecell.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.vcall.com/ClientPage.asp?ID=88641 or http://www.vcall.com/.
About LifeCell
LifeCell is a leader in tissue regeneration through the development and commercialization of biological products for use in reconstructive, urogynecologic and orthopedic surgical procedures. The Company's patented tissue processing methods produce a unique regenerative tissue matrix -- a complex three dimensional structure that contains proteins, growth factors and vascular channels -- that provides a complete template for the regeneration of normal human tissue. LifeCell currently markets a broad range of products: AlloDerm(R), regenerative tissue matrix for skin grafting for burn and cancer patients and for reconstructive surgical procedures, through LifeCell's direct sales organization and for periodontal surgery through BioHorizons, Inc.; Cymetra(R), a version of AlloDerm in particulate form, through LifeCell's direct sales organization and a co-promotion agreement with OMP, Inc.; Repliform(R), regenerative tissue matrix for urogynecologic procedures, through a marketing agreement with Boston Scientific Corporation; Graft Jacket(TM), regenerative tissue matrix for orthopedic applications, through a distribution agreement with Wright Medical Technology, Inc.; and AlloCraft(TM)DBM, regenerative tissue matrix for bone grafting, through a marketing agreement with Stryker Corporation. The Company's ongoing product development programs include the application of its tissue matrix technology to vascular and orthopedic tissue repair; investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion. Visit the LifeCell website at http://www.lifecell.com/.
LifeCell Corporation
What: LifeCell Corporation Second Quarter 2004 Financial Results Conference Call Webcast When: July 22, 2004 @ 11:00 AM Eastern Where: http://www.vcall.com/EventPage.asp?ID=88641 How: Live over the Internet -- Simply log on to the web at the address above. Contact: Marian Smith, (908) 947-1100 or msmith@lifecell.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.vcall.com/ClientPage.asp?ID=88641 or http://www.vcall.com/.
About LifeCell
LifeCell is a leader in tissue regeneration through the development and commercialization of biological products for use in reconstructive, urogynecologic and orthopedic surgical procedures. The Company's patented tissue processing methods produce a unique regenerative tissue matrix -- a complex three dimensional structure that contains proteins, growth factors and vascular channels -- that provides a complete template for the regeneration of normal human tissue. LifeCell currently markets a broad range of products: AlloDerm(R), regenerative tissue matrix for skin grafting for burn and cancer patients and for reconstructive surgical procedures, through LifeCell's direct sales organization and for periodontal surgery through BioHorizons, Inc.; Cymetra(R), a version of AlloDerm in particulate form, through LifeCell's direct sales organization and a co-promotion agreement with OMP, Inc.; Repliform(R), regenerative tissue matrix for urogynecologic procedures, through a marketing agreement with Boston Scientific Corporation; Graft Jacket(TM), regenerative tissue matrix for orthopedic applications, through a distribution agreement with Wright Medical Technology, Inc.; and AlloCraft(TM)DBM, regenerative tissue matrix for bone grafting, through a marketing agreement with Stryker Corporation. The Company's ongoing product development programs include the application of its tissue matrix technology to vascular and orthopedic tissue repair; investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion. Visit the LifeCell website at http://www.lifecell.com/.
LifeCell Corporation
